Candesartan cilexetil

Key facts

Invented name
Blopress and associated names
Active substance
Candesartan cilexetil
Therapeutic area
Cardiovascular diseases
Decision number
P/22/2009
PIP number
Candesartan cilexetil
Pharmaceutical form(s)
  • Tablets
  • Suspension for oral use
Condition(s) / indication(s)
  • Diabetic retinopathy
  • Heart Failure
  • Essential hypertension
Route(s) of administration
Oral use
Contact for public enquiries
Applicant: Takeda Global Research and Development Centre (Europe) Ltd
E-mail: m.mantock@tgrd.com
Country: United Kingdom
Phone: +44 2077595248
Fax: +44 2077595273
Decision type
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan

Decision

How useful was this page?

Add your rating